Recent Research Analysts’ Ratings Updates for Legend Biotech (LEGN)

A number of research firms have changed their ratings and price targets for Legend Biotech (NASDAQ: LEGN):

• 3/20/2026 – Legend Biotech was downgraded by Truist Financial Corporation from “strong-buy” to “hold”.
• 3/11/2026 – Legend Biotech had its price target lowered by Morgan Stanley from $50.00 to $49.00. They now have an “overweight” rating on the stock.
• 3/11/2026 – Legend Biotech had its price target lowered by Royal Bank Of Canada from $66.00 to $62.00. They now have an “outperform” rating on the stock.
• 3/10/2026 – Legend Biotech was given a new $70.00 price target by Truist Financial Corporation.
• 3/10/2026 – Legend Biotech had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $69.00 price target on the stock.
• 3/10/2026 – Legend Biotech was upgraded by Truist Financial Corporation from “hold” to “strong-buy”.
• 2/23/2026 – Legend Biotech had its “outperform” rating reaffirmed by Raymond James Financial, Inc..
• 2/23/2026 – Legend Biotech was downgraded by Truist Financial Corporation from “strong-buy” to “hold”.
• 2/12/2026 – Legend Biotech was downgraded by Rothschild & Co Redburn from “buy” to “neutral”. They now have a $24.00 price target on the stock.
• 2/4/2026 – Legend Biotech had its price target lowered by Barclays PLC from $90.00 to $80.00. They now have an “overweight” rating on the stock.

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.